At the just concluded 25th International Conference on AIDS (AIDS2024), as a major clinical research progress of the conference, Dr. Christian Gaebler of Charlotte University in Berlin, Germany, reported the seventh "next Berlin patient" to be cured after the world's first "Berlin patient" cured of HIV. This patient did not follow the traditional path of achieving cure through homozygous CCR5 Δ 32/Δ 32 stem cell transplantation, but miraculously achieved sustained HIV remission without antiretroviral therapy (ART) for over five years after receiving heterozygous CCR5 WT/Δ 32 stem cell transplantation. Infectious Disease Frontier（IIDF） invited Dr. Christian Gaebler for an in-depth interview to elaborate on the significant implications behind this unprecedented successful case.

Broad spectrum neutralizing antibodies (bnAbs) are showing unprecedented potential in the field of HIV prevention and treatment. At the 25th International AIDS Conference (AIDS2024), Professor Hyman Scott, medical director of Bridge HIV clinical research, San Francisco Department of Public Health, introduced the latest progress of bnAbs in HIV prevention and treatment. Infectious Disease Frontier（IIDF） is honored to invite Professor Scott for an in-depth interview, elaborating on the important role of bnAbs in HIV prevention and treatment. Professor Scott pointed out that bnAbs provides a new option for people at high risk of HIV infection due to its convenience and efficient prevention ability of only requiring one injection every six months. By complementing existing antiretroviral therapies, bnAbs not only enriches prevention methods, but also opens up new pathways for the treatment of HIV infection. In the future, with the deepening of clinical development of bnAbs under the framework of HVTN/HPTN/IAVI cooperation, we are expected to witness the widespread application of this innovative therapy worldwide, bringing new hope to end the AIDS epidemic.